Alder Biopharmaceuticals Inc (NASDAQ:ALDR) was the target of unusually large options trading on Monday. Traders acquired 1,113 put options on the company. This is an increase of 1,924% compared to the average volume of 55 put options.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Alder Biopharmaceuticals by 5.5% in the 2nd quarter. Vanguard Group Inc. now owns 3,626,573 shares of the biopharmaceutical company’s stock valued at $41,525,000 after purchasing an additional 187,871 shares during the period. Janus Henderson Group PLC bought a new stake in Alder Biopharmaceuticals in the 2nd quarter valued at $36,956,000. State Street Corp boosted its stake in Alder Biopharmaceuticals by 9.4% in the 2nd quarter. State Street Corp now owns 1,944,755 shares of the biopharmaceutical company’s stock valued at $22,267,000 after purchasing an additional 167,642 shares during the period. Emerald Advisers Inc. PA boosted its stake in Alder Biopharmaceuticals by 9.6% in the 4th quarter. Emerald Advisers Inc. PA now owns 1,730,028 shares of the biopharmaceutical company’s stock valued at $19,809,000 after purchasing an additional 151,551 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in Alder Biopharmaceuticals by 9.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,661,997 shares of the biopharmaceutical company’s stock valued at $19,030,000 after purchasing an additional 145,503 shares during the period. Institutional investors and hedge funds own 97.22% of the company’s stock.
A number of research analysts recently weighed in on the company. Canaccord Genuity set a $22.00 target price on Alder Biopharmaceuticals and gave the stock a “buy” rating in a report on Friday, January 12th. BMO Capital Markets boosted their target price on Alder Biopharmaceuticals to $26.00 and gave the stock an “outperform” rating in a report on Tuesday, January 9th. BidaskClub lowered Alder Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, December 19th. Mizuho reissued a “buy” rating and set a $29.00 target price (down from $32.00) on shares of Alder Biopharmaceuticals in a report on Tuesday, January 9th. Finally, ValuEngine lowered Alder Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $27.93.
COPYRIGHT VIOLATION NOTICE: “Stock Traders Buy High Volume of Put Options on Alder Biopharmaceuticals (ALDR)” was first posted by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.americanbankingnews.com/2018/02/14/stock-traders-buy-high-volume-of-put-options-on-alder-biopharmaceuticals-aldr.html.
Alder Biopharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.